Phaseline

Companies › OrsoBio

OrsoBio: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Other, Metabolic and endocrine; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TLC-6740–Phase 1Healthy SubjectsJan 2027
TLC-1180–Phase 1Healthy ParticipantsMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05822544TLC-6740Phase 1Healthy SubjectsMetabolic and endocrineJan 2027
NCT07300189TLC-1180Phase 1Healthy ParticipantsOtherMar 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.